Patents by Inventor Jeremy O'CONNELL

Jeremy O'CONNELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240043484
    Abstract: Described herein are polypeptides comprising an FGF17, IGF2, or BMP7 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and/or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
    Type: Application
    Filed: September 20, 2023
    Publication date: February 8, 2024
    Inventors: Hanadie YOUSEF, Jeremy O'CONNELL, Thach MAI, Rami JAAFAR, Zhihua LI
  • Publication number: 20240024423
    Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 25, 2024
    Inventors: Hanadie Yousef, Jeremy O'Connell, Thach Mai
  • Publication number: 20230405089
    Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
    Type: Application
    Filed: February 1, 2023
    Publication date: December 21, 2023
    Applicant: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar
  • Publication number: 20230398187
    Abstract: Described herein are polypeptides comprising an FGF17, IGF2, or BMP? amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and/or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
    Type: Application
    Filed: December 22, 2020
    Publication date: December 14, 2023
    Applicant: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar, Zhihua Li
  • Publication number: 20230312663
    Abstract: Described herein are polypeptides comprising an FGF17, IGF2, or BMP7 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and/or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
    Type: Application
    Filed: February 1, 2023
    Publication date: October 5, 2023
    Applicant: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar, Zhihua Li
  • Publication number: 20220409696
    Abstract: Described herein are polypeptides comprising an IGF2 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Mutations within the IGF2 amino acid sequence improved the stability of the molecule by reducing backbone cleavage. Also described herein are synergistic combinations of an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
    Type: Application
    Filed: June 10, 2022
    Publication date: December 29, 2022
    Applicant: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Jeremy O'Connell, Thach Mai, Zhihua Li
  • Publication number: 20210038693
    Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
    Type: Application
    Filed: October 16, 2020
    Publication date: February 11, 2021
    Applicant: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Jeremy O'Connell, Thach Mai
  • Patent number: 10821155
    Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 3, 2020
    Assignee: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Thach Mai, Jeremy O'Connell
  • Publication number: 20200000882
    Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
    Type: Application
    Filed: June 27, 2019
    Publication date: January 2, 2020
    Inventors: Hanadie YOUSEF, Thach MAI, Jeremy O'CONNELL